ACADIA Pharmaceuticals Inc.
ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 developmā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$22.26
Price+5.65%
$1.19
1Y
Price
Market Cap
$3.795b
Mid
Price/Earnings 3y Avg5y Avg
9.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+9.3%
EBITDA Margin+96.3%
Net Profit Margin-18.6%
Free Cash Flow Margin+9.3%
EBITDA Margin+96.3%
Net Profit Margin-18.6%
Free Cash Flow MarginRevenue
$1.072b
+11.9%
1y CAGR+28.1%
3y CAGR+22.8%
5y CAGREarnings
$391m
+72.7%
1y CAGR+204.6%
3y CAGR+146.3%
5y CAGREPS
$2.29
+68.4%
1y CAGR+202.8%
3y CAGR+145.2%
5y CAGRBook Value
$1.227b
$1.564b
Assets$336.805m
Liabilities$52.187m
DebtDebt to Assets
3.3%
0.4x
Debt to EBITDAFree Cash Flow
$105.146m
-33.1%
1y CAGR+273.2%
3y CAGR+207.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company